Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study
…, P Rao-Melacini, S Rangarajan, S Islam, P Pais… - The Lancet, 2010 - thelancet.com
Background The contribution of various risk factors to the burden of stroke worldwide is
unknown, particularly in countries of low and middle income. We aimed to establish the …
unknown, particularly in countries of low and middle income. We aimed to establish the …
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
…, D Xavier, CM Atisso, L Dyal, S Hall, P Rao-Melacini… - The Lancet, 2019 - thelancet.com
Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …
Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study
…, L Liu, H Zhang, P Rao-Melacini, X Zhang, P Pais… - The lancet, 2016 - thelancet.com
Background Stroke is a leading cause of death and disability, especially in low-income and
middle-income countries. We sought to quantify the importance of potentially modifiable risk …
middle-income countries. We sought to quantify the importance of potentially modifiable risk …
[HTML][HTML] Randomized trial of benznidazole for chronic Chagas' cardiomyopathy
…, L Bonilla, B Meeks, P Rao-Melacini… - … England Journal of …, 2015 - Mass Medical Soc
… 2.79 (95% CI, 1.99 to 3.92) at 5 or more years (P<0.001 for interaction). However, the rates
of PCR conversion did not correspond to effects on clinical outcome (P=0.16 for interaction). …
of PCR conversion did not correspond to effects on clinical outcome (P=0.16 for interaction). …
Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes
Background— Although preventive drug therapy is a priority after acute coronary syndrome,
less is known about adherence to behavioral recommendations. The aim of this study was to …
less is known about adherence to behavioral recommendations. The aim of this study was to …
Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study
… The 30-day mortality rate was 11.6% (48 of 415 patients) among patients who had a
perioperative MI and 2.2% (178 of 7936 patients) among those who did not (P < 0.001). Among …
perioperative MI and 2.2% (178 of 7936 patients) among those who did not (P < 0.001). Among …
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
…, D Xavier, CM Atisso, L Dyal, S Hall, P Rao-Melacini… - The Lancet, 2019 - thelancet.com
Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes
in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-…
in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-…
The influence of economic development level, household wealth and maternal education on child health in the developing world
…, S Hong, W Omariba, P Hurley, P Rao-Melacini - Social science & …, 2006 - Elsevier
This study estimates the relative importance to child health (indicated by weight and height
for age) of economic development level [gross domestic product (GDP) converted to …
for age) of economic development level [gross domestic product (GDP) converted to …
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial
…, SJ Connolly, SI Bangdiwala, P Rao-Melacini… - The Lancet, 2018 - thelancet.com
Background Myocardial injury after non-cardiac surgery (MINS) increases the risk of
cardiovascular events and deaths, which anticoagulation therapy could prevent. Dabigatran …
cardiovascular events and deaths, which anticoagulation therapy could prevent. Dabigatran …
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
…, L Rydén, CM Atisso, S Hall, P Rao-Melacini… - The Lancet …, 2020 - thelancet.com
Background Diabetes is an independent risk factor for cognitive impairment. We aimed to
investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist …
investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist …
